These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17114213)

  • 1. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer.
    Schrohl AS; Meijer-van Gelder ME; Holten-Andersen MN; Christensen IJ; Look MP; Mouridsen HT; Brünner N; Foekens JA
    Clin Cancer Res; 2006 Dec; 12(23):7054-8. PubMed ID: 17114213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.
    Willemoe GL; Hertel PB; Bartels A; Jensen MB; Balslev E; Rasmussen BB; Mouridsen H; Ejlertsen B; Brünner N
    Eur J Cancer; 2009 Sep; 45(14):2528-36. PubMed ID: 19535243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
    Foekens JA; Peters HA; Grebenchtchikov N; Look MP; Meijer-van Gelder ME; Geurts-Moespot A; van der Kwast TH; Sweep CG; Klijn JG
    Cancer Res; 2001 Jul; 61(14):5407-14. PubMed ID: 11454684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
    Er O; Frye DK; Kau SW; Broglio K; Valero V; Hortobagyi GN; Arun B
    Cancer J; 2008; 14(1):62-8. PubMed ID: 18303485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.
    Yang W; Klos KS; Zhou X; Yao J; Yang Y; Smith TL; Shi D; Yu D
    Cancer; 2003 Sep; 98(6):1123-30. PubMed ID: 12973835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer.
    Klintman M; Ørnbjerg Würtz S; Christensen IJ; Braemer Hertel P; Fernö M; Malmberg M; Mouridsen H; Cold F; Schrohl AS; Foekens JA; Malmström P; Brünner N
    Breast Cancer Res Treat; 2010 Jun; 121(2):365-71. PubMed ID: 19653096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients.
    Ejlertsen B; Jensen MB; Nielsen KV; Balslev E; Rasmussen BB; Willemoe GL; Hertel PB; Knoop AS; Mouridsen HT; Brünner N
    J Clin Oncol; 2010 Feb; 28(6):984-90. PubMed ID: 20038724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer.
    Jaremko M; Justenhoven C; Schroth W; Abraham BK; Fritz P; Vollmert C; Illig T; Simon W; Schwab M; Brauch H
    Pharmacogenet Genomics; 2007 Jul; 17(7):529-38. PubMed ID: 17558308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue inhibitor metalloproteinase type-1 (TIMP-1), a novel cancer biomarker predicting response of adjuvant anthracycline-based chemotherapy in patients afflicted with primary breast cancer.
    Schmitt M; Sweep FC
    Eur J Cancer; 2009 Sep; 45(14):2444-6. PubMed ID: 19647994
    [No Abstract]   [Full Text] [Related]  

  • 11. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
    Knoop AS; Knudsen H; Balslev E; Rasmussen BB; Overgaard J; Nielsen KV; Schonau A; Gunnarsdóttir K; Olsen KE; Mouridsen H; Ejlertsen B;
    J Clin Oncol; 2005 Oct; 23(30):7483-90. PubMed ID: 16234514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.
    Pierceall WE; Sprott KM; Heikkinen T; Heikkila P; Alaparthi L; Aittomaki K; Al-Adhami M; Villegas-Bergazzi V; Meyer JL; Kutok JL; Bartkova J; Bartek J; Nevanlinna H; Weaver DT; Blomqvist C
    Hum Pathol; 2012 Sep; 43(9):1363-75. PubMed ID: 22204715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens.
    Sládek NE; Kollander R; Sreerama L; Kiang DT
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):309-21. PubMed ID: 11914911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High levels of uPA and PAI-1 predict a good response to anthracyclines.
    Borstnar S; Sadikov A; Mozina B; Cufer T
    Breast Cancer Res Treat; 2010 Jun; 121(3):615-24. PubMed ID: 20039121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success.
    Span PN; Lindberg RL; Manders P; Tjan-Heijnen VC; Heuvel JJ; Beex LV; Sweep CG
    J Pathol; 2004 Apr; 202(4):395-402. PubMed ID: 15095266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
    Tinari N; Lattanzio R; Natoli C; Cianchetti E; Angelucci D; Ricevuto E; Ficorella C; Marchetti P; Alberti S; Piantelli M; Iacobelli S
    Clin Cancer Res; 2006 Mar; 12(5):1501-6. PubMed ID: 16533774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure.
    Derenzini M; Donati G; Mazzini G; Montanaro L; Vici M; Ceccarelli C; Santini D; Taffurelli M; Treré D
    Clin Cancer Res; 2008 Apr; 14(7):2199-209. PubMed ID: 18381962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy.
    Végran F; Boidot R; Oudin C; Riedinger JM; Bonnetain F; Lizard-Nacol S
    Clin Cancer Res; 2006 Oct; 12(19):5794-800. PubMed ID: 17020986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study.
    Schrohl AS; Look MP; Meijer-van Gelder ME; Foekens JA; Brünner N
    BMC Cancer; 2009 Sep; 9():322. PubMed ID: 19744322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.